Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 861-881

  Delgado Alvarado, Manuel ^a,b   Gago, Belén ^a,b,g   Navalpotro Gomez, Irene ^a,b   Jiménez Urbieta, Haritz ^a,b   Rodriguez Oroz, María C ^a,b,c,d,e,f  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

^e BASQUE CENTER ON COGNITION   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Biomarkers; Dementia; Mild cognitive impairment; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR STIMULATING AGENT; SOMATOMEDIN; URIC ACID;

BODY FLUID; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; BRAIN REGION; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOPAMINERGIC ACTIVITY; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC BACKGROUND; GRAY MATTER; HUMAN; INFORMATION RETRIEVAL; LONGITUDINAL STUDY; MAGNETOENCEPHALOGRAPHY; MILD COGNITIVE IMPAIRMENT; NEUROPHYSIOLOGY; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR; URIC ACID BLOOD LEVEL; URINE; WHITE MATTER; BLOOD; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING;

BIOMARKERS; COGNITIVE DYSFUNCTION; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 84971219296     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26662     Document Type: Review

References (298)

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-844.
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60(3):387-392.
3. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26(10):1814-1824.
4. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21(9):1343-1349.
5. Gasca-Salas C, Estanga A, Clavero P, et al. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's Disease. J Parkinsons Dis 2014;4(4):677-686.
6. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013;70(5):580-586.
7. Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013;81(4):346-352.
8. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349-356.
9. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58(5):773-776.
10. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23(3):295-297.
11. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64(8):1404-1410.
12. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134(Pt 5):1493-1505.
13. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014;29(5):634-650.
14. Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120(6):827-828.
15. Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012;119(3):381-382.
16. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22(3):200-208.
17. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25(15):2682-2685.
18. Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015;262(2):294-306.
19. Compta Y, Ezquerra M, Munoz E, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease. Neurosci Lett 2011;487(2):169-173.
20. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34(1):107-112.
21. Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19(8):717-724.
22. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75(12):1055-1061.
23. Liu C, Cholerton B, Shi M, et al. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21(3):271-276.
24. Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front Aging Neurosci 2014;6:53.
25. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24(15):2203-2210.
26. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69(11):1445-1452.
27. Jansen Steur E, Vermes I, de Vos RA. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 1998;351(9109):1105-1106.
28. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64(10):850-855.
29. Vranová HP, Henykova E, Kaiserova M, et al. Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 2014;343(1-2):120-124.
30. Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 2012;7(10):e48042.
31. Beyer MK, Alves G, Hwang KS, et al. Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease. Mov Disord 2013;28(3):302-310.
32. Yu SY, Zuo LJ, Wang F, et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol 2014;14(1):113.
33. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81(10):1080-1086.
34. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17(1):61-64.
35. Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord 2015;21(7):758-764.
36. Wennström M, Surova Y, Hall S, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013;8(1):e53250.
37. Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014;6(3):25.
38. Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014;184(4):966-975.
39. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol Aging 2015;36(1):476-484.
40. Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183-189.
41. Maetzler W, Stapf AK, Schulte C, et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 2011;27(1):119-126.
42. Maetzler W, Schmid B, Synofzik M, et al. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010;19(3):937-942.
43. Kuiper MA, Mulder C, van Kamp GJ, Scheltens P, Wolters EC. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neural Transm Park Dis Dement Sect 1994;7(2):109-114.
44. Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009;132(Pt 12):3308-3317.
45. Jesse S, Lehnert S, Jahn O, et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS ONE 2012;7(11):e48783.
46. Lehnert S, Jesse S, Rist W, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012;234(2):499-505.
47. Backstrom DC, Eriksson Domellof M, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson Disease. JAMA Neurol 2015;72(10):1175-1182.
48. Bialecka M, Kurzawski M, Roszmann A, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet Genomics 2012;22(10):716-724.
49. Song IU, Kim JS, Park IS, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). Arch Gerontol Geriatr 2013;57(3):288-291.
50. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61(6):865-868.
51. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009;24(10):1437-1444.
52. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29(6):305-311.
53. Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 2009;24(2):176-182.
54. Peterson AL, Murchison C, Zabetian C, et al. Memory, mood, and vitamin d in persons with Parkinson's disease. J Parkinsons Dis 2013;3(4):547-555.
55. Gonzalez-Aramburu I, Sanchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(6):637-639.
56. Song IU, Kim YD, Cho HJ, Chung SW. Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease? Intern Med 2013;52(16):1787-1792.
57. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008;14(7):576-578.
58. Moccia M, Picillo M, Erro R, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? Parkinsonism Relat Disord 2014;20(7):772-775.
59. Moccia M, Picillo M, Erro R, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. Eur J Neurol 2014.
60. Menza M, Dobkin RD, Marin H, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010;51(6):474-479.
61. Scalzo P, Kummer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010;468(1):56-58.
62. Rocha NP, Scalzo PL, Barbosa IG, et al. Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease. Parkinsons Dis 2014;2014:903796.
63. Pellecchia MT, Santangelo G, Picillo M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol 2013;260(2):438-444.
64. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69(4):655-663.
65. Pellecchia MT, Santangelo G, Picillo M, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson's disease. Eur J Neurol 2014;21(5):802-807.
66. Ma J, Jiang Q, Xu J, et al. Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord 2015;93(5-6):251-256.
67. Angelucci F, Peppe A, Carlesimo GA, et al. A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. Front Hum Neurosci 2015;9:130.
68. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9(1):92-97.
69. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-S36; discussion S36-28.
70. Li Z, Zhang J, Sun H. Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment. J Clin Neurosci 2015;22(8):1268-1271.
71. Pratico D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147(1):1-10.
72. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn Behav Neurol 2008;21(2):83-86.
73. Mielke MM, Maetzler W, Haughey NJ, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS ONE 2013;8(9):e73094.
74. Witt SN. Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration. Commun Integr Biol 2014;7(6):e993266.
75. Norris SE, Friedrich MG, Mitchell TW, Truscott RJ, Else PL. Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. Neurobiol Aging 2015;36(4):1659-1669.
76. von Bernhardi R, Eugenin-von Bernhardi L, Eugenin J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 2015;7:124.
77. Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72(17):1487-1494.
78. Blazquez L, Otaegui D, Saenz A, et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett 2006;406(3):235-239.
79. Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol Scand 2006;113(1):14-17.
80. Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006;21(1):45-49.
81. Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci Lett 2007;414(2):141-144.
82. Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord 2014;20(5):503-507.
83. Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 2014;71(11):1405-1412.
84. Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37(2):242-245.
85. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79(3):458-461.
86. Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord 2005;20(8):989-994.
87. Jasinska-Myga B, Opala G, Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007;64(2):261-265.
88. Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. Neurosci Lett 2008;448(1):20-23.
89. Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol 2009;22(3):166-170.
90. Troster AI, Fields JA, Paolo AM, Koller WC. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease. J Neurol Sci 2006;248(1-2):62-67.
91. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256(3):493-498.
92. Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012;27(4):512-518.
93. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009;24(3):392-400.
94. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62(8):1265-1269.
95. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54(6):1272-1276.
96. Setó-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011;68(3):359-364.
97. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(Pt 11):2958-2969.
98. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62(2):145-153.
99. Winder-Rhodes SE, Hampshire A, Rowe JB, et al. Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging 2015;36(3):1519-1528.
100. Nishioka K, Ross OA, Ishii K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009;24(12):1811-1819.
101. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55(2):174-179.
102. Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E, Zarranz JJ. Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1). J Neurol Sci 2011;310(1-2):86-89.
103. Tokutake T, Ishikawa A, Yoshimura N, et al. Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat Disord 2014;20(2):262-264.
104. De Marco EV, Tarantino P, Rocca FE, et al. Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147(3):403-407.
105. Seto-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord 2012;27(3):393-399.
106. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78(18):1434-1440.
107. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010;32(7):775-779.
108. Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015;30(3):407-411.
109. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136(Pt 2):392-399.
110. Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013;45(8):511-521.
111. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007;27(18):4832-4838.
112. Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19(8):885-891.
113. Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain 2008;131(Pt 2):397-408.
114. Hoogland J, de Bie RM, Williams-Gray CH, Muslimovic D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010;25(15):2550-2554.
115. Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014;137(Pt 10):2743-2758.
116. Hudson G, Stutt A, Eccles M, et al. Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. Neurosci Lett 2010;479(2):123-125.
117. Nie K, Zhang Y, Gan R, et al. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neurosci Lett 2013;541:111-115.
118. Bialecka M, Kurzawski M, Roszmann A, et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci Lett 2014;561:86-90.
119. Guerini FR, Beghi E, Riboldazzi G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol 2009;16(11):1240-1245.
120. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127(Pt 4):791-800.
121. Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS ONE 2013;8(1):e54980.
122. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64(5):861-865.
123. Choi SH, Jung TM, Lee JE, Lee SK, Sohn YH, Lee PH. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging 2012;33(7):1265-1272.
124. Borroni B, Premi E, Formenti A, et al. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. Parkinsonism Relat Disord 2015;21(9):1049-1055.
125. Biundo R, Calabrese M, Weis L, et al. Anatomical correlates of cognitive functions in early Parkinson's disease patients. PLoS ONE 2013;8(5):e64222.
126. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15(2):88-93.
127. Mak E, Zhou J, Tan LC, Au WL, Sitoh YY, Kandiah N. Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. J Neurol Neurosurg Psychiatry 2014;85(5):576-580.
128. Noh SW, Han YH, Mun CW, et al. Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment. J Neurol Sci 2014;347(1-2):210-213.
129. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010;25(6):687-695.
130. Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18(8):941-947.
131. Kenny ER, Burton EJ, O'Brien JT. A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008;26(3):218-225.
132. Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005;20(5):540-544.
133. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003;18(7):784-790.
134. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64(2):224-229.
135. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62(2):281-285.
136. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78(3):254-259.
137. Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011;26(2):289-296.
138. Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83(2):188-194.
139. Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord 2012;27(6):727-734.
140. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008;255(9):1324-1331.
141. Nishio Y, Hirayama K, Takeda A, et al. Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 2010;17(8):1090-1097.
142. Weintraub D, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011;68(12):1562-1568.
143. Hwang KS, Beyer MK, Green AE, et al. Mapping cortical atrophy in Parkinson's disease patients with dementia. J Parkinsons Dis 2013;3(1):69-76.
144. Lee SH, Kim SS, Tae WS, Lee SY, Lee KU, Jhoo J. Brain volumetry in Parkinson's disease with and without dementia: where are the differences? Acta Radiol 2013;54(5):581-586.
145. Zarei M, Ibarretxe-Bilbao N, Compta Y, et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84(8):875-881.
146. Pereira JB, Svenningsson P, Weintraub D, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 2014;82(22):2017-2025.
147. Kim HJ, Lee JE, Shin SJ, Sohn YH, Lee PH. Analysis of the substantia innominata volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and Alzheimer's disease. J Mov Disord 2011;4(2):68-72.
148. Hanganu A, Bedetti C, Jubault T, et al. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord 2013;28(10):1360-1369.
149. Danti S, Toschi N, Diciotti S, et al. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality. Eur J Neurol 2015;22(12):1564-1572.
150. Segura B, Baggio HC, Marti MJ, et al. Cortical thinning associated with mild cognitive impairment in Parkinson's disease. Mov Disord 2014;29(12):1495-1503.
151. Lee JE, Park B, Song SK, Sohn YH, Park HJ, Lee PH. A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov Disord 2010;25(1):28-34.
152. Mak E, Su L, Williams GB, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2015;138(Pt 10):2974-2986.
153. Hattori T, Orimo S, Aoki S, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012;33(3):727-739.
154. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology 1996;46(3):678-681.
155. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75(10):1467-1469.
156. Oikawa H, Sasaki M, Ehara S, Abe T. Substantia innominata: MR findings in Parkinson's disease. Neuroradiology 2004;46(10):817-821.
157. Filoteo JV, Reed JD, Litvan I, Harrington DL. Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. Mov Disord 2014;29(3):360-367.
158. Camicioli R, Gee M, Bouchard TP, et al. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism Relat Disord 2009;15(3):187-195.
159. Ibarretxe-Bilbao N, Junque C, Tolosa E, et al. Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci 2009;30(6):1162-1171.
160. Duncan GW, Firbank MJ, Yarnall AJ, et al. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? Mov Disord 2016;31(1):103-110.
161. Koshimori Y, Segura B, Christopher L, et al. Imaging changes associated with cognitive abnormalities in Parkinson's disease. Brain Struct Funct 2015;220(4):2249-2261.
162. Garcia-Diaz AI, Segura B, Baggio HC, et al. Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease. Parkinsonism Relat Disord 2014;20(12):1405-1410.
163. Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014;85(1):7-16.
164. Kandiah N, Zainal NH, Narasimhalu K, et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(11):1203-1208.
165. Morales DA, Vives-Gilabert Y, Gomez-Anson B, et al. Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Res 2013;213(2):92-98.
166. Melzer TR, Watts R, MacAskill MR, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 2013;80(20):1841-1849.
167. Kamagata K, Motoi Y, Abe O, et al. White matter alteration of the cingulum in Parkinson disease with and without dementia: evaluation by diffusion tensor tract-specific analysis. Am J Neuroradiol 2012;33(5):890-895.
168. Kamagata K, Motoi Y, Tomiyama H, et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol 2013;23(7):1946-1955.
169. Deng B, Zhang Y, Wang L, et al. Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease. Am J Alzheimers Dis Other Demen 2013;28(2):154-164.
170. Matsui H, Nishinaka K, Oda M, Niikawa H, Kubori T, Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007;116(3):177-181.
171. Agosta F, Canu E, Stefanova E, et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp 2014;35(5):1921-1929.
172. Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. Eur J Radiol 2015;84(7):1318-1324.
173. Agosta F, Canu E, Stojkovic T, et al. The topography of brain damage at different stages of Parkinson's disease. Hum Brain Mapp 2013;34(11):2798-2807.
174. Zheng Z, Shemmassian S, Wijekoon C, Kim W, Bookheimer SY, Pouratian N. DTI correlates of distinct cognitive impairments in Parkinson's disease. Hum Brain Mapp 2014;35(4):1325-1333.
175. Theilmann RJ, Reed JD, Song DD, et al. White-matter changes correlate with cognitive functioning in Parkinson's disease. Front Neurol 2013;4:37.
176. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012;11(8):679-687.
177. Nagano-Saito A, Habak C, Mejia-Constain B, et al. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiol Aging 2014;35(1):223-231.
178. Ekman U, Eriksson J, Forsgren L, et al. Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment. Front Neurosci 2014;8:207.
179. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23(15):6351-6356.
180. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84(11):1258-1264.
181. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23(7):998-1005.
182. Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 2012;263(1):226-234.
183. Rektorova I, Krajcovicova L, Marecek R, Mikl M. Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia. Neurodegener Dis 2012;10(1-4):232-237.
184. Baggio HC, Sala-Llonch R, Segura B, et al. Functional brain networks and cognitive deficits in Parkinson's disease. Hum Brain Mapp 2014;35(9):4620-4634.
185. Pereira JB, Aarsland D, Ginestet CE, et al. Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Hum Brain Mapp 2015;36(8):2980-2995.
186. Amboni M, Tessitore A, Esposito F, et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. J Neurol 2015;262(2):425-434.
187. Olde Dubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 2014;83(22):2046-2053.
188. Rektorova I, Krajcovicova L, Marecek R, Novakova M, Mikl M. Default mode network connectivity patterns associated with visual processing at different stages of Parkinson's disease. J Alzheimers Dis 2014;42(suppl 3):S217-S228.
189. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013;19(3):329-334.
190. Summerfield C, Gomez-Anson B, Tolosa E, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002;59(9):1415-1420.
191. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008;22(1):54-60.
192. Pagonabarraga J, Gomez-Anson B, Rotger R, et al. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease. Dement Geriatr Cogn Disord 2012;34(5-6):312-318.
193. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004;354(3):177-180.
194. Lewis SJ, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord 2012;27(10):1262-1267.
195. Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123(Pt 2):340-352.
196. Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002;125(Pt 6):1358-1365.
197. Christopher L, Marras C, Duff-Canning S, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain 2014;137(Pt 2):565-575.
198. Chou KL, Lenhart A, Koeppe RA, Bohnen NI. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 2014;20(10):1076-1080.
199. Christopher L, Duff-Canning S, Koshimori Y, et al. Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol 2015;77(2):269-280.
200. van Beilen M, Leenders KL. Putamen FDOPA uptake and its relationship tot cognitive functioning in PD. J Neurol Sci 2006;248(1-2):68-71.
201. Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov Disord 2010;25(1):35-43.
202. Siepel FJ, Bronnick KS, Booij J, et al. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. Mov Disord 2014;29(14):1802-1808.
203. Pellecchia MT, Picillo M, Santangelo G, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand 2015;131(5):275-281.
204. Bruck A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001;311(2):81-84.
205. Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. Mov Disord 2008;23(11):1580-1587.
206. Lebedev AV, Westman E, Simmons A, et al. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Front Syst Neurosci 2014;8:45.
207. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005;32(10):1176-1185.
208. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166(2):141-151.
209. Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord 2013;27(1):51-55.
210. Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol 2015;129(4):527-540.
211. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21(4):456-461.
212. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74(11):885-892.
213. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73(4):273-278.
214. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40(3):399-410.
215. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65(11):1716-1722.
216. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-1748.
217. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253(2):242-247.
218. Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009;66(8):866-877.
219. Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012;32(8):1609-1617.
220. Bohnen NI, Albin RL, Muller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015;72(2):194-200.
221. Lorenz R, Samnick S, Dillmann U, et al. Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurol Scand 2014;130(3):164-171.
222. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-1338.
223. Shimada H, Shinotoh H, Hirano S, et al. beta-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013;28(2):169-175.
224. Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012;79(11):1161-1167.
225. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39(3):1027-1033.
226. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74(1):77-84.
227. Campbell MC, Markham J, Flores H, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013;81(6):520-527.
228. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012;27(8):965-973.
229. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25(15):2516-2523.
230. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80(1):85-91.
231. Lucero C, Campbell MC, Flores H, Maiti B, Perlmutter JS, Foster ER. Cognitive reserve and beta-amyloid pathology in Parkinson disease. Parkinsonism Relat Disord 2015;21(8):899-904.
232. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72(4):587-598.
233. Petrou M, Dwamena BA, Foerster BR, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015;30(7):928-935.
234. Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord 2005;20(8):999-1005.
235. Matsui H, Udaka F, Miyoshi T, et al. N-isopropyl-p- 123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia. Intern Med 2005;44(10):1046-1050.
236. Derejko M, Slawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun 2006;27(12):945-951.
237. Wallin A, Ekberg S, Lind K, Milos V, Granerus AK, Granerus G. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease-a rCBF scintigraphy study. Acta Neurol Scand 2007;116(6):347-354.
238. Wang SJ, Liu RS, Liu HC, et al. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur J Nucl Med 1993;20(4):339-344.
239. Liu RS, Lin KN, Wang SJ, et al. Cognition and 99Tcm-HMPAO SPECT in Parkinson's disease. Nucl Med Commun 1992;13(10):744-748.
240. Spampinato U, Habert MO, Mas JL, et al. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1991;54(9):787-792.
241. Kawabata K, Tachibana H, Sugita M. Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol 1991;4(4):194-203.
242. Kasama S, Tachibana H, Kawabata K, Yoshikawa H. Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging. Dement Geriatr Cogn Disord 2005;19(5-6):266-275.
243. Hattori N, Yabe I, Hirata K, et al. Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT. Clin Nucl Med 2013;38(5):315-320.
244. Nobili F, Abbruzzese G, Morbelli S, et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009;24(3):414-421.
245. Song IU, Chung YA, Chung SW, Jeong J. Early diagnosis of Alzheimer's disease and Parkinson's disease associated with dementia using cerebral perfusion SPECT. Dement Geriatr Cogn Disord 2014;37(5-6):276-285.
246. Matsui H, Nishinaka K, Oda M, et al. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat Disord 2007;13(3):174-181.
247. Sawada H, Udaka F, Kameyama M, et al. SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992;55(10):960-963.
248. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001;22(1):45-46.
249. Mito Y, Yoshida K, Yabe I, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005;107(5):396-403.
250. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013;38(6):938-949.
251. Garcia-Garcia D, Clavero P, Gasca Salas C, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging 2012;39(11):1767-1777.
252. Gonzalez-Redondo R, Garcia-Garcia D, Clavero P, et al. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain 2014;137(Pt 8):2356-2367.
253. Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16(10):666-670.
254. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14(12):1357-1362.
255. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 Pt 2):1470-1477.
256. Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009;24(6):854-862.
257. Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010;64(2):65-73.
258. Pappata S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77(14):1357-1362.
259. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52(6):848-855.
260. Shoji Y, Nishio Y, Baba T, et al. Neural substrates of cognitive subtypes in Parkinson's disease: a 3-year longitudinal study. PLoS ONE 2014;9(10):e110547.
261. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34(2):714-723.
262. Huang C, Ravdin LD, Nirenberg MJ, et al. Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord 2013;35(3-4):183-196.
263. Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 2004;22(2):553-561.
264. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22(3):236-245.
265. Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 2003;74(4):419-422.
266. Paschali A, Messinis L, Lyros E, et al. Neuropsychological functions and rCBF SPECT in Parkinson's disease patients considered candidates for deep brain stimulation. Eur J Nucl Med Mol Imaging 2009;36(11):1851-1858.
267. Kramberger MG, Stukovnik V, Cus A, et al. Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment. Psychiatr Danub 2010;22(3):446-449.
268. Neufeld MY, Inzelberg R, Korczyn AD. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 1988;78(1):1-5.
269. Neufeld MY, Blumen S, Aitkin I, Parmet Y, Korczyn AD. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia 1994;5(1):23-28.
270. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008;131(Pt 3):690-705.
271. Serizawa K, Kamei S, Morita A, et al. Comparison of quantitative EEGs between Parkinson disease and age-adjusted normal controls. J Clin Neurophysiol 2008;25(6):361-366.
272. Soikkeli R, Partanen J, Soininen H, Paakkonen A, Riekkinen P Sr. Slowing of EEG in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1991;79(3):159-165.
273. Fonseca LC, Tedrus GM, Carvas PN, Machado EC. Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia. Clin Neurophysiol 2013;124(10):1970-1974.
274. Domitrz I, Friedman A. Electroencephalography of demented and non-demented Parkinson's disease patients. Parkinsonism Relat Disord 1999;5(1-2):37-41.
275. Caviness JN, Hentz JG, Evidente VG, et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord 2007;13(6):348-354.
276. Bousleiman H, Zimmermann R, Ahmed S, et al. Power spectra for screening parkinsonian patients for mild cognitive impairment. Ann Clin Transl Neurol 2014;1(11):884-890.
277. Klassen BT, Hentz JG, Shill HA, et al. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology 2011;77(2):118-124.
278. Caviness JN, Hentz JG, Belden CM, et al. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. J Parkinsons Dis 2015;5(1):117-124.
279. Schlede N, Zimmermann R, Ehrensperger MM, et al. Clinical EEG in cognitively impaired patients with Parkinson's Disease. J Neurol Sci 2011;310(1-2):75-78.
280. Morita A, Kamei S, Mizutani T. Relationship between slowing of the EEG and cognitive impairment in Parkinson disease. J Clin Neurophysiol 2011;28(4):384-387.
281. Zimmermann R, Gschwandtner U, Hatz F, et al. Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease. Dement Geriatr Cogn Disord 2015;39(3-4):207-214.
282. Kamei S, Morita A, Serizawa K, Mizutani T, Hirayanagi K. Quantitative EEG analysis of executive dysfunction in Parkinson disease. J Clin Neurophysiol 2010;27(3):193-197.
283. Bosboom JL, Stoffers D, Stam CJ, et al. Resting state oscillatory brain dynamics in Parkinson's disease: an MEG study. Clin Neurophysiol 2006;117(11):2521-2531.
284. Bosboom JL, Stoffers D, Wolters E, Stam CJ, Berendse HW. MEG resting state functional connectivity in Parkinson's disease related dementia. J Neural Transm 2009;116(2):193-202.
285. Picton TW, Bentin S, Berg P, et al. Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria. Psychophysiology 2000;37(2):127-152.
286. Hanafusa H, Motomura N, Fukai M. Event-related potentials in senile dementia of Alzheimer's type, multiinfarct dementia and Parkinson's disease. Jpn J Psychiatry Neurol 1991;45(3):667-670.
287. Toda K, Tachibana H, Sugita M, Konishi K. P300 and reaction time in Parkinson's disease. J Geriatr Psychiatry Neurol 1993;6(3):131-136.
288. Ito J. Somatosensory event-related potentials (ERPs) in patients with different types of dementia. J Neurol Sci 1994;121(2):139-146.
289. O'Mahony D, Rowan M, Feely J, O'Neill D, Walsh JB, Coakley D. Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison. Gerontology 1993;39(4):228-240.
290. Matsui H, Nishinaka K, Oda M, Kubori T, Udaka F. Auditory event-related potentials in Parkinson's disease: prominent correlation with attention. Parkinsonism Relat Disord 2007;13(7):394-398.
291. Tanaka H, Koenig T, Pascual-Marqui RD, Hirata K, Kochi K, Lehmann D. Event-related potential and EEG measures in Parkinson's disease without and with dementia. Dement Geriatr Cogn Disord 2000;11(1):39-45.
292. Pang S, Borod JC, Hernandez A, et al. The auditory P 300 correlates with specific cognitive deficits in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1990;2(4):249-264.
293. Bodis-Wollner I, Borod JC, Cicero B, et al. Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;9(2-3):197-209.
294. Aotsuka A, Weate SJ, Drake ME Jr, Paulson GW. Event-related potentials in Parkinson's disease. Electromyogr Clin Neurophysiol 1996;36(4):215-220.
295. Chen KJ, Lin RT, Liu CK, Tai CT, Lai CL. Relationship between event-related potentials and frontal-subcortical dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2006;12(7):453-458.
296. Bokura H, Yamaguchi S, Kobayashi S. Event-related potentials for response inhibition in Parkinson's disease. Neuropsychologia 2005;43(6):967-975.
297. Celebi O, Temucin CM, Elibol B, Saka E. Short latency afferent inhibition in Parkinson's disease patients with dementia. Mov Disord 2012;27(8):1052-1055.
298. Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? Mov Disord 2013;28(9):1285-1288.